Adie Viljoen

Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial

Melanie J. Davies, Louise Færch, Ole Kleist Jeppesen et al. · The Lancet · 2021 · 1.2K citations

Obesity, Diabetes Management, Medicine +6

Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial

Richard E. Pratley, Vanita R. Aroda, Ildiko Lingvay et al. · The Lancet Diabetes & Endocrinology · 2018 · 714 citations

Metabolic Syndrome, Diabetes Management, Diabetes +9

Efficacy and safety of once-weekly semaglutide versus daily canagliflozin as add-on to metformin in patients with type 2 diabetes (SUSTAIN 8): a double-blind, phase 3b, randomised controlled trial

Ildiko Lingvay, Andrei‐Mircea Catarig, Juan P. Frías et al. · The Lancet Diabetes & Endocrinology · 2019 · 265 citations · Full text

Diabetes Management, Sustain 8, Medicine +6

Anti-interleukin-21 antibody and liraglutide for the preservation of β-cell function in adults with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled, phase 2 trial

Matthias von Herrath, Stephen C. Bain, Bruce W. Bode et al. · The Lancet Diabetes & Endocrinology · 2021 · 163 citations · Full text

Inflammation, β-Cell Function, Diabetes Management +7

Relationship between Serum Copper, Ceruloplasmin, and Non–Ceruloplasmin-Bound Copper in Routine Clinical Practice

Patrick J. Twomey, Adie Viljoen, Ivan House et al. · Clinical Chemistry · 2005 · 128 citations · Full text

Non–ceruloplasmin-bound Copper, Pathology, Low Serum Copper +18